Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026)
Immix Biopharma (IMMX) posted Accumulated Expenses of $880671.0 for Q1 2026, down 6.53% sequentially from $942163.0 in Q4 2025, and up 20.34% YoY from $731794.0 in Q1 2025.
Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Accumulated Expenses for 7 years, with the latest figure at $880671.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 20.34% year-over-year to $880671.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $880671.0 (up 20.34% YoY) and the FY2025 annual result came in at $942163.0, up 627.16% from the prior year.
- Accumulated Expenses declined to $880671.0 in Q1 2026 per IMMX's latest filing, from $942163.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $942163.0 in Q4 2025 and troughed at $9407.0 in Q1 2022.
- A 5-year average of $311351.2 and a median of $170632.0 in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 4715.87% in 2022, then plunged 76.95% in 2023.
- Over 5 years, Accumulated Expenses stood at $438196.0 in 2022, then slumped by 76.95% to $101007.0 in 2023, then advanced by 28.28% to $129567.0 in 2024, then jumped by 627.16% to $942163.0 in 2025, then retreated by 6.53% to $880671.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $880671.0, $942163.0, and $170896.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 173,282.00 |
| Mar 31, 2026 | 880,671.00 |
| Dec 31, 2025 | 942,163.00 |
| Sep 30, 2025 | 170,896.00 |
| Jun 30, 2025 | 52,940.00 |
| Mar 31, 2025 | 731,794.00 |
| Dec 31, 2024 | 129,567.00 |
| Sep 30, 2024 | 198,095.00 |
| Jun 30, 2024 | 170,632.00 |
| Mar 31, 2024 | 122,594.00 |
| Dec 31, 2023 | 101,007.00 |
| Sep 30, 2023 | 99,603.00 |
| Dec 31, 2022 | 438,196.00 |
| Mar 31, 2022 | 9,407.00 |
| Dec 31, 2021 | 9,099.00 |
| Dec 31, 2020 | 342,837.00 |